SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave's stock is trending amid high trading volume and anticipation surrounding its earnings report, with revenue backlog growth being a key focus. Community discussions revolve around whether recent price declines present a buying opportunity, with some highlighting the company's fundamentals and long-term potential in the AI infrastructure space, while others express concern about debt and potential delays.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as investors discuss its recent private placement and potential partnership with Nvidia, with some expressing concerns about dilution while others see it as a strategic move. The community is weighing short-term pain against long-term growth prospects in the AI data center market. Overall sentiment is mixed, with some hoping for a bounce and others anticipating further downside.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is trending as investors discuss its recent earnings report, which beat expectations despite a year-over-year revenue decline, and the acquisition of Ask Sage, a generative AI platform. Community talking points include the potential for government contracts, comparisons to Palantir (PLTR), and speculation about a short squeeze, with many expressing optimism for future growth in the AI sector.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending as the community rallies behind recent positive catalysts, including a major institutional investment and the CEO's planned purchase of $1 million in stock. Discussions center on the potential for a short squeeze and the impact of upcoming warrants, with many expressing bullish sentiment. The stock's significant price movement and high trading volume are also drawing attention.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

Anavex Life Sciences ($AVXL) is trending as investors eagerly anticipate the EMA's decision on Blarcamesine, their Alzheimer's drug, with an oral explanation scheduled. Community discussions revolve around the potential for approval, the implications of a smaller, single trial, and the possibility of a partnership or buyout. Some traders are noting aggressive options activity and expressing caution, while others remain bullish, emphasizing the drug's safety profile and long-term data.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap ($UNI) is trending as the community anticipates potential benefits from a governance upgrade that could redirect trading fees to UNI holders and the DAO treasury. Bullish sentiment is fueled by the protocol's high annualized fees and discussions around potential breakouts. Some traders are also watching for a bullish pennant formation, while others cite the possibility of a burn.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors discuss the upcoming data release from its HOPE-3 trial for Duchenne Muscular Dystrophy, with expectations building ahead of the company's conference call. Community sentiment seems cautiously optimistic, with focus on potential FDA approval and the drug's impact on cardiomyopathy, a leading cause of death in DMD patients. Discussions also include potential label expansion and the value of the StealthX exosome platform.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CLSK is trending as investors digest the implications of a recent convertible note offering; while some view it as a strategic move to raise capital for expansion and potential share buybacks, others express concerns about potential dilution and debt burden. The community is actively debating the company's pivot towards AI and data centers, and how this offering will impact their ability to compete. Some traders point to short selling activity related to the convertible notes as a factor influencing the stock.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors discuss its Q3 earnings beat and anticipation surrounding the Neutron rocket program, despite a minor delay to its launch schedule. The community highlights the company's strong financial performance, government contract potential, and strategic acquisitions like GEOST. Bullish sentiment is fueled by the belief that Rocket Lab is well-positioned for long-term growth in the space industry.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending due to its recent acquisition announcement and a large private placement, which has shifted the company's focus to hematologic malignancies. The community is discussing the potential for a short squeeze, given the low float and high borrowing costs, while some traders express caution due to the stock's high volatility and overbought conditions. Bullish investors are hoping for a multi-day run, while bears anticipate a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bloomberg Surveillance 11/10/2025

Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern speak daily with leaders and decision makers from Wall Street to Washington and beyond. No other program better positions investors and executives...

Instacart Up on Earnings Beat; Metsera Down on Takeover Battle  Stock Movers

On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading after Novo Nordisk A/S declined to further raise its offer for the US maker of an experimental...

Dividend Stocks To Keep An Eye On - November 9th

ProShares UltraPro Short QQQ, Pfizer, Direxion Daily TSLA Bull 2X Shares, Exxon Mobil, and AT&T are the five Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend...

Eli Lilly cuts surprising deals with upstart biotech players

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated...

Best Value Stocks Worth Watching - November 10th

Invesco QQQ, Sandisk, CoreWeave, Pfizer, and AltC Acquisition are the five Value stocks to watch today, according to MarketBeat's stock screener tool. Value stocks are shares of companies that appear...

Dividend Stocks To Watch Now - November 10th

Pfizer, Direxion Daily TSLA Bull 2X Shares, and ProShares UltraPro Short QQQ are the three Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks are shares of...

Promising Pharmaceutical Stocks To Add to Your Watchlist - November 10th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, AbbVie, Metsera, AstraZeneca, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Medical Stocks To Watch Today - November 10th

Eli Lilly and Company, Pfizer, UnitedHealth Group, Intuitive Surgical, and Movano are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares...

Shutdown Hopes Rise; St. Louis Fed's Musalem & AQR's Cliff Asness  Open Interest 11/10/2025

Get a jump start on the US trading day with Matt Miller and Dani Burger on 'Bloomberg Open Interest.' Democrats concede on health care, setting up a potential breakthrough to end the longest shutdown...

<ul class="summary-bullets"><li>Pfizer CEO Albert Bourla made candid remarks on live television regarding the Seagen acquisition and the Metsera deal.</li><li>Seagen, acquired for $43 billion in 2023, is expected to add $10 billion to Pfizer’s risk-adjusted revenue by 2030.</li><li>Bourla said the Metsera deal positions Pfizer to compete more effectively in the obesity drug market against Eli Lilly and Novo Nordisk.</li></ul>Pfizer (PFE) CEO Albert Bourla reportedly dropped the F-bomb on live television while discussing the company’s Seagen acquisition and how lessons learned might influence its outlook on the Metsera (MTSR) deal.Quoting Jim Carmer, Bourla said, “If the whole things fails, then we overpaid. If the whole things succeeds, it’s a f- - -ing good deal.” He added that the deal with Seagen was “transformational” for Pfizer and a driver for its oncology department.On the success of Mastera, he said more data would be needed to determine its success. “Once we get approval, we’ll find out,” Bourla stated.<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> edged 0.4% lower in morning trade, despite strength in the broader market. On Stocktwits, retail sentiment around the company trended in ‘extremely bullish’ territory as chatter dipped to ‘high’ from ‘extremely high’ levels over the past day.<h2 class="st-heading-2">Pfizer’s Seagen Acquisition</h2>Pfizer acquired Seagen, a biotechnology company that specialized in antibody-drug conjugates (ADCs) for cancer therapy, in 2023 for $43 billion. According to the company, the deal is expected to add more than $10 billion to Pfizer’s risk-adjusted revenue by 2030. Pfizer also noted that Seagen nearly doubled the company’s pipeline with 60 programs and added four FDA-approved cancer drugs.&nbsp;<h2 class="st-heading-2">Outlook For Metsera Deal</h2>Bourla stated that the crux of the Metsera deal was that it allows Pfizer to expand its footprint in the “fastest growing market” for obesity drugs. “In our hands, it can create significant value.”He added that the addition of Metsera to Pfizer’s portfolio puts the company in a better position to compete against Eli Lilly (LLY) and Novo Nordisk (NOVO). “All we wanted was the right portfolio, because ours, unfortunately, ours didn’t work,” Bourla told CNBC.He also expects that Pfizer will pay out the full contingent value right (CVR), which grants shareholders additional payments if certain milestones are met with respect to drug development and commercial success.Pfizer won the bidding war for Metsera against Novo Nordisk last week, putting up more than $10 billion to acquire the weight-loss drug startup.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/open-ai-reportedly-exploring-consumer-healthcare-push-with-ai-assistants-and-data-tools/cLPcLr2REcy">OpenAI Reportedly Exploring Consumer Healthcare Push With AI Assistants And Data Tools</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Deals

Quoting Jim Carmer, Pfizer CEO Albert Bourla said, “If the whole things fails, then we overpaid. If the whole things succeeds, it’s a f- - -ing good deal.” 

Pfizer CEO Reportedly Drops F-Bomb On Live TV Discussing Seagen, Metsera Deals 

Equity

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

$NVDA

$MSFT

$AAPL

$GOOGL

Which of these Mag 7 stocks are you most bullish on right now?

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PFE News

PFEPfizer Inc